Clinical trial
Phase 1 Study OF CDC-501 in Patients With Solid Tumors
NCT00046735 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00046735 |
|---|---|
| Title | Phase 1 Study OF CDC-501 in Patients With Solid Tumors |
| Official title | A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Lenalidomide |
| Enrollment | 24 |
| Start date | Jun 1, 2002 |
| Primary completion | Aug 1, 2006 |
| Completion | Sep 28, 2006 |
| First posted | Oct 3, 2002 |
| Last update posted | Nov 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: